Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

MREO Financial Statements and Analysis

NASDAQ : MREO

Mereo BioPharma Group plc

$2.21
-0.16-6.75%
At Close 4:00 PM
50
BESG ScoreESG Rating

MREO FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

MREO Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue000361.10K533.429K
cost of revenue0257.288K274.842K216.922K172.897K
gross profit0-257.288K-274.842K144.178K360.532K
gross profit ratio0000.3990.676
research and development expenses3.17M4.946M3.994M2.886M3.188M
general and administrative expenses6.203M7.868M5.906M2.456M2.776M
selling and marketing expenses00000
selling general and administrative expenses6.203M7.868M5.906M2.456M2.776M
other expenses00000
operating expenses9.373M12.814M9.90M6.393M7.031M
cost and expenses9.373M12.814M9.90M6.61M7.204M
interest income983.00K559.00K617.00K13.084K202.456
interest expense353.00K331.00K310.00K00
depreciation and amortization282.00K257.00K274.842K188.522K198.455K
ebitda-14.366M-12.049M-8.838M-5.504M-5.967M
ebitda ratio000-15.243-11.186
operating income-9.373M-12.814M-9.90M-5.693M-6.165M
operating income ratio000-15.765-11.558
total other income expenses net-5.628M559.00K949.00K-109.359K-158.686K
income before tax-15.001M-12.255M-8.951M-5.802M-6.324M
income before tax ratio000-16.068-11.856
income tax expense00-476.727K244.466K235.58K
net income-15.001M-12.255M-8.951M-6.047M-6.56M
net income ratio000-16.745-12.297
eps-100.02-86.117-63.913-0.044-0.047
eps diluted-100.02-86.117-63.913-0.044-0.047
weighted average shs out770.147M711.772M700.271M138.366M138.366M
weighted average shs out dil770.147M711.771M700.263M138.364M138.364M
Graph

MREO Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDGBP
calendar year20242024202420232023
periodQ3Q2Q1Q4Q2
cash and cash equivalents80.522M87.431M48.66M57.421M42.113M
short term investments00000
cash and short term investments80.522M87.431M48.66M57.421M42.113M
net receivables2.843M2.673M2.15M3.732M10.739M
inventory01.001.822M1.247M-2.846M
other current assets3.358M3.836M2.686M1.36M4.222M
total current assets86.723M93.94M53.496M63.76M54.228M
property plant equipment net1.224M1.323M1.469M1.65M1.564M
goodwill00000
intangible assets799.00K866.00K972.00K1.089M24.845M
goodwill and intangible assets799.00K866.00K972.00K1.089M24.845M
long term investments00000
tax assets00000
other non current assets00001.00K
total non current assets2.023M2.189M2.441M2.739M26.41M
other assets00000
total assets88.746M96.129M55.937M66.499M80.638M
account payables1.748M2.70M2.455M2.346M1.911M
short term debt736.00K5.61M4.331M652.00K4.674M
tax payables2.276M2.297M391.00K662.00K0
deferred revenue003.22M6.458M9.487M
other current liabilities9.448M4.859M3.827M30.00K1.386M
total current liabilities14.208M15.466M11.004M9.486M17.458M
long term debt394.00K552.00K727.00K5.30M4.638M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities1.608M1.461M1.368M1.176M797.00K
total non current liabilities2.002M2.013M2.095M6.476M5.435M
other liabilities00000
capital lease obligations1.13M1.231M1.389M1.558M1.461M
total liabilities16.21M17.479M13.099M15.962M22.893M
preferred stock00000
common stock3.051M3.032M2.775M2.775M1.93M
retained earnings-455.837M-440.836M-428.581M-419.63M-342.194M
accumulated other comprehensive income loss-11.104M-18.278M-18.283M-17.485M141.724M
other total stockholders equity536.426M534.732M486.927M484.877M256.285M
total stockholders equity72.536M78.65M42.838M50.537M57.745M
total equity72.536M78.65M42.838M50.537M57.745M
total liabilities and stockholders equity88.746M96.129M55.937M66.499M80.638M
minority interest00000
total investments00000
total debt1.13M6.162M6.019M5.952M9.312M
net debt-79.392M-81.269M-42.641M-51.469M-32.801M
Graph

MREO Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2024Mar 31, 2024Jun 30, 2023Jun 30, 2020
reported currencyUSDUSDUSDGBP
calendar year2024202420232020
periodQ2Q1Q2Q2
deferred income tax0000
stock based compensation2.088M2.05M00
change in working capital1.66M-1.505M-7.852M20.237M
accounts receivables-370.537K-476.727K-6.808M-276.50K
inventory0000
accounts payables241.187K126.927K00
other working capital1.79M-1.155M-1.043M20.514M
other non cash items3.082M3.089M4.227M41.564M
net cash provided by operating activities-7.914M-7.986M-16.728M0
investments in property plant and equipment381.00-699.60K-415.58K0
acquisitions net0000
purchases of investments0000
sales maturities of investments0000
other investing activites1.00K-700.00K019.50K
net cash used for investing activites381.00-699.60K-415.58K19.50K
debt repayment-219.068K00-17.452M
common stock issued47.015M02.466K0
common stock repurchased0000
dividends paid0000
other financing activites46.781M097.42K42.228M
net cash used provided by financing activities46.796M0-178.81K24.777M
effect of forex changes on cash-107.00K-70.00K3.099M0
net change in cash38.771M-8.761M-14.224M24.796M
cash at end of period87.431M48.66M53.54M24.796M
cash at beginning of period48.66M57.421M67.764M0
operating cashflow-7.914M-7.986M-16.728M0
capital expenditure381.00-699.60K-415.58K0
free cash flow-7.913M-8.686M-17.144M0
Graph

Frequently Asked Questions

How did Mereo BioPharma Group plc do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, MREO generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Mereo BioPharma Group plc report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Mereo BioPharma Group plc reported a $0.00 Gross Profit for the quarter ended Jun 30, 2024.
Have MREO's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. MREO incurred $9.37M worth of Operating Expenses, while it generated -$9.37M worth of Operating Income.
How much Net Income has MREO posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Mereo BioPharma Group plc, the company generated -$15.00M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Mereo BioPharma Group plc have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Mereo BioPharma Group plc as of the end of the last quarter was $80.52M.
What are MREO's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, MREO had Total Net Receivables of $2.84M.
In terms of Total Assets and Current Assets, where did Mereo BioPharma Group plc stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of MREO were $86.72M, while the Total Assets stand at $88.75M.
As of the last quarter, how much Total Debt did Mereo BioPharma Group plc have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of MREO's debt was $1.13M at the end of the last quarter.
What were MREO's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, MREO reported total liabilities of $16.21M.
How much did MREO's Working Capital change over the last quarter?
Working Capital Change for MREO was $1.66M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
MREO generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. MREO generated -$7.91M of Cash from Operating Activities during its recently reported quarter.
What was MREO's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. MREO reported a $38.77M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph